Business Wire·Sep 10, 2026, 4:03 PM ET

Yarrow Bioscience Announces Proposed Underwritten Public Offering

Yarrow Bioscience, Inc. (NASDAQ: YARW) commenced an underwritten public offering of common stock or pre-funded warrants to purchase common stock.
The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares at the public offering price.
Net proceeds from the offering will fund research & development expenses, working capital, capital expenditures, and general corporate purposes.
Jefferies, TD Cowen, Guggenheim Securities, and LifeSci Capital are acting as joint book-running managers or lead manager for the offering.
A shelf registration statement on Form S-3 was declared effective by the SEC on August 19, 2026.
Yarrow is a clinical-stage biotechnology company developing YB-101, a first-in-class anti-TSH receptor monoclonal antibody for autoimmune thyroid diseases.